KOSPIBiotech & Pharma293480

Hana Pharm

₩8,060▼ 0.37%2026-11-18 close
Market Cap
₩143.2B
Turnover
₩86,736,970
Volume
10K
Shares out.
17.8M
PER
5.4×
PBR
0.4×
EPS
₩1,490
Dividend Yield
3.24%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩260 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales up, margins down: the export shift is the test

Hana Pharm's revenue rose each year from 2023 through 2025, yet its operating margin slid from 14.8% in 2022 to 10.8% in 2025, making the Pyeongtaek plant and Bavipo exports the next key variables.

  1. 1

    2025 revenue reached KRW 239.5 billion, the highest of 2022 to 2025, while profit attributable to controlling shareholders fell 58.7% to KRW 8.78 billion.

  2. 2

    Export share was only 0.3% in 2024 and 0.94% in cumulative terms through the third quarter of 2025.

  3. 3

    The company plans to invest KRW 56.76 billion in a new Pyeongtaek plant, funded partly by a treasury share disposal and a sale of its stake in another listed pharmaceutical company worth KRW 23.357 billion.

  4. 4

    Hana Pharm was designated an insincere-disclosure firm in July 2026, and total cash dividends for 2026 fell about 48% from the prior year.

  5. 5

    Bavipo's domestic sales topped KRW 10 billion in 2025, and the company set a 2026 global export target of KRW 15 billion.

02

Business structure

Hana Pharm is a prescription-drug-focused pharmaceutical company whose growth has been led by its cardiovascular and narcotic/anesthetic product lines. Cardiovascular product sales rose from KRW 66.9 billion in 2022 to KRW 71.9 billion in 2023 and KRW 72.9 billion in 2024.

Sales of the narcotic and anesthetic product group were reported to have exceeded KRW 50 billion in 2024. The company says high entry barriers in narcotics and anesthetics support revenue stability.

Its injectable business gained capacity of roughly KRW 200 billion after the Hagil plant's injectable facility was completed in 2022, compared with a prior ceiling that kept sales in the KRW 40 billion range.

The flagship anesthetic Bavipo (remimazolam) was licensed from a German company, with domestic rights and production rights for six Southeast Asian countries. Exports remain small: in 2024 they totaled KRW 724 million, or 0.3% of sales.

Products made at the domestic plant are distributed across Europe by a German partner. In R&D, the company has described P-CAB, a reflux-disease candidate, as approaching Phase 1 entry. Its MRI contrast agent HNP-2006 was discontinued in 2024 due to technical and manufacturing-stability problems.

Domestic-market dependence is pronounced compared with major pharmaceutical peers, whose export shares are considerably higher.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩63.8B₩8.3B13.1%
2025Q4₩60.4B₩5.8B9.7%
2026Q1₩62.3B₩7.1B11.4%
2026Q2₩60.9B₩7.3B12.0%
2026Q3₩59.4B₩6.4B10.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩210.8B₩31.2B₩24.3B14.8%9.1%28.9%
2023₩224.5B₩27B₩22.3B12.0%8.0%25.3%
2024₩225.3B₩25.2B₩21.3B11.2%6.9%23.6%
2025₩239.5B₩25.8B₩8.8B10.8%2.8%33.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported annual basis, revenue rose from KRW 210.8 billion in 2022 to KRW 224.5 billion in 2023 (up 6.5%), KRW 225.3 billion in 2024 (up 0.4%) and KRW 239.5 billion in 2025 (up 6.3%). Growth slowed sharply to 0.4% in 2024 before picking up again in 2025.

Operating profit went from KRW 31.2 billion in 2022 to KRW 27 billion in 2023 (down 13.3%) and KRW 25.2 billion in 2024 (down 6.9%), then edged up 2.6% to KRW 25.8 billion in 2025. Operating margin declined from 14.8% in 2022 to 12.0%, 11.2% and 10.8% in 2025.

The margin was 18.3% in 2021, so the erosion is a longer trend. Cost pressure is visible in the first half of 2025, when the cost-of-sales ratio rose to 38.3% from 36.3% a year earlier while the SG&A ratio held at 51.6%.

Profit attributable to controlling shareholders fell from KRW 24.3 billion in 2022 to KRW 22.3 billion in 2023 (down 8.1%), KRW 21.3 billion in 2024 (down 4.8%) and KRW 8.78 billion in 2025 (down 58.7%).

In 2025 operating profit rose slightly while net profit fell sharply, widening the gap between the two; the below-operating-line drivers should be checked in the annual report footnotes.

On a quarterly basis, the company moved from a controlling-shareholder net loss of KRW 4.26 billion in the third quarter of 2025 to net profit of KRW 3.27 billion in the fourth quarter.

Profit attributable to controlling shareholders then reached KRW 10 billion in the first quarter of 2026, up 206.1% from the prior quarter, and declined over the next two quarters to KRW 8.45 billion and KRW 4.59 billion.

Third-quarter 2026 revenue was KRW 59.4 billion, down 6.8% year on year, and operating profit was KRW 6.39 billion, down 23.4%. The effect of the May 2026 stake sale on profit from the second quarter onward is a point to check in quarterly filings.

Over the last four quarters, profit attributable to controlling shareholders totaled KRW 26.3 billion. Equity at the end of 2025 was KRW 313.4 billion and total liabilities KRW 104.7 billion, with the debt ratio rising from 23.6% in 2024 to 33.4% in 2025.

Operating cash flow was KRW 30.9 billion in 2022, KRW 18.4 billion in 2023, KRW 25.3 billion in 2024 and KRW 9.18 billion in 2025.

05

Industry analysis

In the domestic pharmaceutical industry, an aging population and rising chronic-disease prevalence are cited as steady demand drivers. Generic-focused business models, however, are directly exposed to drug-pricing policy.

Industry analysis links the margin pressure to generic price-cut policy, currency and raw-material volatility, and a domestic-focused business structure. Narcotics and anesthetics are described as a segment with high entry barriers.

A Sangsangin Securities researcher said in a July 2026 article that Bavipo could grow to roughly KRW 40 billion in sales within two to three years in a domestic market of about KRW 110 billion; this is a broker's estimate, not company guidance.

Relative to major pharmaceutical peers, Hana Pharm's export share is low, so whether its anesthetic portfolio can differentiate it from mid-sized domestic rivals depends on export results.

An industry observer noted that without a link between capex, margins and overseas revenue, a revaluation of market capitalization is difficult. On the production side, the Hagil CMO plant has obtained both EU-GMP and K-GMP certification.

The company said it was the first to obtain EU-GMP for a lyophilized injectable new drug that is also a psychotropic substance. Data for judging where the sector stands in its cycle are limited; demand is growing gradually while pricing policy weighs on margins. The strategic direction is summarized as export expansion and cost improvement.

06

Outlook

The most important near-term milestone is the new Pyeongtaek plant. Construction started on April 23, 2026, with completion targeted for October 18, 2026. Because that target date has passed, the completion filing and the start of operations are the next points to check.

The company plans to put KRW 23.4 billion from the stake sale into building the new injectable facility, which it expects will strengthen production capacity and also support Bavipo export expansion. For 2026, the company set a global export target of KRW 15 billion.

Bavipo's contract-manufacturing volumes for Europe and Japan are expected to expand from 2026, and talks are ongoing with partners in Thailand, Vietnam and Malaysia.

In its April 2026 value-up plan, the company set R&D strengthening and export expansion as core goals, alongside cost reduction, production efficiency and flexible shareholder returns. Whether operating margin and export results in the 2026 annual report track those goals is the next verifiable point.

07

Valuation

PER
5.4×
PBR
0.4×
ROE
8.2%
EPS
₩1,490
BPS
₩19,429
Dividend per share
₩260

Hana Pharm's share price has stayed well below its IPO offering price since its 2018 listing, and its market capitalization has fallen sharply from its first-day close. The price-to-book ratio sits well below 1x, meaning the share price is under the book value of net assets.

The price-to-earnings multiple depends heavily on the earnings base, so after profit declined in 2025, its reading depends on the 2026 earnings trend. Total cash dividends for 2026 fell about 48% from the prior year, and the company's standing as a high-dividend stock has come under question.

Industry observers argue that the margin decline makes a premium valuation difficult, and that the shares have traded in a range. Multiples move with the share price, so they are best read alongside whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Growth path of Bavipo

Bavipo's domestic sales topped KRW 10 billion in 2025. A Sangsangin Securities researcher said in a July 2026 article that sales could reach around KRW 40 billion within two to three years in a domestic market of about KRW 110 billion. The company set a 2026 global export target of KRW 15 billion, and Japanese shipments began in July 2025.

Injectable capacity and the new plant

After the Hagil injectable plant opened in 2022, the company gained production capacity of roughly KRW 200 billion. It plans to invest KRW 23.4 billion from the stake sale in a new Pyeongtaek plant, which it expects will strengthen injectable production. The Hagil plant holds both EU-GMP and K-GMP certification, providing a base for overseas quality credentials.

Quarterly earnings resilience

Quarterly operating profit held above KRW 6 billion through 2026, at KRW 7.11 billion in the first quarter, KRW 7.29 billion in the second and KRW 6.39 billion in the third. Profit attributable to controlling shareholders reached KRW 10 billion in the first quarter of 2026, up 206.1% from the prior quarter.

Over the last four quarters, that profit totaled KRW 26.3 billion, following a net loss in the third quarter of 2025.

09

Bear factors

Continued margin erosion

Operating margin declined from 18.3% in 2021 to 10.8% in 2025. The cost-of-sales ratio rose in the first half of 2025, and third-quarter 2026 operating profit fell 23.4% year on year, so the pace of profit recovery is not yet clear.

Export share stuck near 1%

Export share was 0.94% in cumulative terms through the third quarter of 2025, and it has never exceeded 1% since listing. Although contract-manufacturing agreements with Japan were worth about KRW 57.3 billion as of 2025, actual overseas revenue growth is seen as limited.

Weaker dividend appeal

Total dividends paid in 2026 were KRW 4.58 billion, about 48% below the KRW 8.82 billion paid the prior year. That raises doubts about whether the company can keep its high-dividend status, a concern for holders who valued its payout.

10

Risk factors

Liquidity and investment burden

The new Pyeongtaek plant carries an investment of KRW 56.76 billion. Cash and equivalents were about KRW 0.9 billion at the end of the first half of 2025, down nearly 90% from KRW 8.5 billion at the end of 2024. Short-term borrowings of KRW 24.5 billion fall due within a year.

The company raised funds through a treasury share disposal and the stake sale, but delayed returns on the investment could keep financial pressure elevated.

Disclosure-control credibility

A disposal equal to 7.45% of equity was disclosed roughly a month after the sale, and the stake-holding figure for a vice president was later corrected downward. A fine of about KRW 12 million was imposed with no penalty points, but a repeat violation within a year could be treated as an aggravating factor.

Concentration in products and pipeline

If Bavipo's overseas revenue remains slow to materialize, the growth case weakens. Despite contracts and domestic approvals, substantive overseas sales growth has been minimal.

In R&D, the MRI contrast agent HNP-2006 was halted after receiving government funding, leaving the pipeline thin and product concentration high.

11

What to watch next

  1. 2026 annual report filing (by end-March 2027)

    Check whether the 2026 operating margin and export results meet the KRW 15 billion export target.

  2. After December 2026 (timing not set)

    Confirm the completion filing and start of operations at the Pyeongtaek plant; the October 18, 2026 target has already passed.

  3. Year-end dividend decision in early 2027 (typically late February to March)

    Check total dividend payout and whether the high-dividend company criteria are still met.

  4. Around May 15, 2027 (first-quarter report deadline)

    Check first-quarter 2027 operating margin and how the stake-sale proceeds are reflected in profit.

  5. Until early July 2027

    The one-year aggravating-factor window from the July 2026 insincere-disclosure designation ends around then; check whether disclosure controls improve.

12

Overall view

Hana Pharm's revenue rose from 2023 through 2025 to KRW 239.5 billion, but operating margin fell from 14.8% in 2022 to 10.8% in 2025, and profit attributable to controlling shareholders dropped to KRW 8.78 billion in 2025.

Quarterly results in 2026 peaked in the first quarter and then declined for two consecutive quarters, while profit attributable to controlling shareholders over the last four quarters totaled KRW 26.3 billion.

Supporting factors include Bavipo's domestic sales growth, injectable capacity, and quarterly operating profit holding above KRW 6 billion. Offsetting factors include export share near 1%, rising cost ratios, cash pressure from the Pyeongtaek plant, the insincere-disclosure designation and lower dividends.

The next checkpoints are export and margin results in the 2026 annual report, completion of the Pyeongtaek plant, and the 2027 dividend decision. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. medipana.com
  4. hanaph.co.kr
  5. businesspost.co.kr
  6. thebionews.net
  7. pinpointnews.co.kr
  8. pharm.edaily.co.kr
  9. dailypharm.com
  10. digitaltoday.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. alphasquare.co.kr
  17. alphasquare.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis